Abstract 16P
Background
Ovarian cancer (OC) is the second gynecological malignancy among women and presents high rates of recurrence associated with chemoresistance. Tumor cells adjust their energy metabolism in favor of their rapid progression. Melatonin (Mel), a hormone produced and secreted by the pineal gland during darkness, has obvious anti-tumor activities. Therefore, we investigated the mechanistic role of Mel on energy metabolism in human OC cells (SKOV-3 and CAISMOV24 cells), with special focus on glycolytic metabolism in addition to cell signaling molecules.
Methods
Cell lines were treated with Mel at concentrations of 3.4 μM for SKOV-3 and 7 μM for CAISMOV24 based on the cell cytotoxicity (CC50) for 24 h; a luzindole-treated group was used to test the influence of melatonin receptors, MT1 and MT2. Protein levels of glycolytic enzymes were analyzed by western blot and kinase levels were measured by multiplex assay.
Results
Melatonin levels dropped by half in the OC cells. We observed a significant decline in the levels of HIF-1α, G6PDH, GAPDH, LDH, and PDH in OC cells treated with melatonin regardless of the presence of luzindole, thus proving its receptor-independent actions; conversely, the luzindole-exposed groups had an upregulation of these proteins. In regard to kinases signaling, SKOV-3 cells treated with melatonin had a reduction in the concentration of CREB, JNK, NF-kB, p-38, ERK1/2, Akt, p70s6k, STAT3, and STAT5, all of them associated with tumor growth, metastasis, and recruitment of oncostatic components. In the CAISMOV24 cells, these molecules were reduced after the combination of melatonin with luzindole.
Conclusions
These findings showed that melatonin potentially regulates energy-related processes in OC cells, thereby favoring the reversal of the Warburg effect, in addition to attenuating cell signaling involved with tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Biosciences of Botucatu.
Funding
CAPES, FAPESP (grant number: 2021/12971-7), CNPq (304108/2020-0).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
53P - Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
Presenter: Francesco Bertoni
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC
Presenter: Tina Jost
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells
Presenter: Martin Hohenegger
Session: Cocktail & Poster Display session
Resources:
Abstract
56P - Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma
Presenter: Kelsey Gauthier
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Deciphering the role of E2F transcription factor-1 in glutamine metabolism
Presenter: Katharina Huber
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low-expressing breast cancer cells and organoid mode
Presenter: Maryam Arshad
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - The influence of the ABCB1, ABCG2 and OATP1 transporters and the CYP3A enzyme on the bioavailability and tissue distribution of TPX-0131
Presenter: Jamie Rijmers
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
Presenter: Emilien Ezine
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma
Presenter: Jiyoon Jung
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
Presenter: ANGSHUMAN SARKAR
Session: Cocktail & Poster Display session
Resources:
Abstract